Key result
Among 152 patients on triple antithrombotic therapy after PCI, the risk of ischemic and bleeding complications (overall NACE 52%) was similar between those on ticagrelor and clopidogrel.
Why the study?
Does ticagrelor compared to clopidogrel in triple antithrombotic therapy alter the risk of ischemic and bleeding complications in patients post-PCI?
Population
152 patients discharged on triple antithrombotic therapy (TT) after percutaneous coronary intervention (PCI)
Comparison
Ticagrelor as part of triple antithrombotic… vs Clopidogrel as part of triple antithrombotic…
Design
Cohort
Follow-up
12 months
Authors
Loading...
May support similar ticagrelor or clopidogrel use in triple therapy post-PCI; leaves open optimal choice pending randomized trials.
Cohort (n=152)
Does ticagrelor compared to clopidogrel in triple antithrombotic therapy alter the risk of ischemic and bleeding complications in patients post-PCI?
In patients on triple antithrombotic therapy post-PCI, ticagrelor and clopidogrel have similar rates of ischemic and bleeding complications, though bridging anticoagulation with ticagrelor may increase adverse events.
Fu et al. (2016) conducted a cohort in Patients on triple antithrombotic therapy after percutaneous coronary intervention (n=152). Ticagrelor vs. Clopidogrel was evaluated on Composite of ischemic (death, myocardial infarction, stroke) and major bleeding complications or net adverse clinical event (NACE). Among 152 patients on triple antithrombotic therapy after PCI, the risk of ischemic and bleeding complications (overall NACE 52%) was similar between those on ticagrelor and clopidogrel.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: